Cyanotic Raynaud's phenomenon with conventional but not with liposomal amphotericin B: three case reports.
Despite its common adverse effects intravenous (i.v.) amphotericin B is an indispensable antifungal drug in childhood oncology. We report here on three cases of painful cyanotic Raynaud's phenomenon after i.v. administration or inhalation of amphotericin B. A liposomal i.v. preparation of amphotericin B was well tolerated by the infants. Spasms of peripheral vessels mediated by thromboxane A2 could be responsible for the Raynaud's phenomenon. Hence, inhibitors of prostaglandin synthesis are suggested for therapy.
Zernikow
B
B
Department of Paediatric, Haematology/Oncology, University Children's Hospital, University of Bonn, Germany.
Fleischhack
G
G
Hasan
C
C
Bode
U
U
D000280:Administration, Inhalation; D000293:Adolescent; D000666:Amphotericin B / Q000009:adverse effects* / Q000627:therapeutic use; D000935:Antifungal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D003490:Cyanosis / Q000139:chemically induced*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007951:Leukemia, Myeloid / Q000188:drug therapy; D015477:Leukemia, Myelomonocytic, Chronic / Q000188:drug therapy; D008081:Liposomes / Q000627:therapeutic use*; D017728:Lymphoma, Large-Cell, Anaplastic / Q000188:drug therapy; D008297:Male; D011928:Raynaud Disease / Q000139:chemically induced*
D000935:Antifungal Agents; D008081:Liposomes; D000666:Amphotericin B